PARK2 Modifies Synucleinopathy Figure 4. Distribution of PS129-a-synuclein- and ubiquitin-immunolabelling in symptomatic hA30Pa-syn mice. (A) Schematic illustration of the distribution and density of PS129-a-synuclein deposits on representative brain coronal sections of symptomatic mice. Similar distributions were observed in hA30Pa-syn mice with or without Parkin. Regions immunolabelled in most animals are indicated in red, whereas those less frequently stained are in grey. (B) Representative micrographs illustrating PS129-a-synuclein-immunolabelling in the brainstem (bregma 22.9) of symptomatic hA30Pa-syn mice with and without Parkin, and in a healthy hA30Pa-syn control mouse. Quantitative analysis of the density of PS129-a-synuclein-labelling in a representative region of the brainstem of symptomatic mice (n = 5 per genotype). (C) Representative micrographs illustrating typical ubiquitin-immunoreactivity in the presence or absence of Parkin in the brainstem of symptomatic mice, and of a healthy hA30Pa-syn control mouse. 1- superior colliculus, 2- pretectal nuclei, 3- geniculate nuclei, 4- periaqueductal grey layer, 5- zona incerta, 6- ventral tegmental area, 7- SN pars reticulata, 8- cerebellar white layer, 9- lateral cerebellar nuclei, 10- vestibular nuclei, 11- cochlear nuclei 12- trigeminal nuclei, 13- pontine reticular nuclei, 14- parvicellular reticular nuclei. Scale bars indicate 200 mm. doi:10.1371/journal.pone.0006629.g004 PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6629